Prevention of Contrast Induced Nephropathy after Endovascular Therapy combined with Carbon Dioxide-digital subtraction angiography in Patients With Ilio-Femoropopliteal artery diseases
Not Applicable
- Conditions
- peripheral artery disease
- Registration Number
- JPRN-UMIN000011988
- Lead Sponsor
- Sakakibara Heart Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Life expectancy 6 months. 2)without regular dialysis 3)under 30years old 4)inappropriate patient determined from study director. 5)patient unavailable of anti platelet agents and anticoagulant. 6)Allergy of contrast agents.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie CO2-DSA's protective effects against contrast-induced nephropathy in peripheral artery disease patients?
How does CO2-digital subtraction angiography compare to standard iodinated contrast agents in preventing nephropathy after endovascular therapy?
Which biomarkers are associated with risk of contrast-induced nephropathy in ilio-femoropopliteal artery disease patients undergoing endovascular procedures?
What are the potential adverse events and management strategies for CO2-DSA use in peripheral arterial disease interventions?
Are there combination approaches involving CO2-angiography and nephroprotective agents that improve outcomes in peripheral vascular disease patients?